Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Nick Pavlakis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1738-0316; OpenAlex author ID A5005287915, A5036532264, A5085372050, A5112814465. Sources: ClinicalTrials.gov.

Their work

Papers
32 (first author 1, last author 3)
Trials
1
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2014: 2 papers · 2015: 2 papers, 1 trial · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 4 papers · 2022: 5 papers · 2023: 5 papers · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 32

  1. Validation of the PANAMA Score in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Distal Pancreatectomy. Co-author DOI 10.1111/ans.70999↗
  2. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  3. Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies. Co-author DOI 10.1016/j.addr.2025.115647↗
  4. SPAN-C: Results of a Phase II Clinical Trial of Stereotactic Body Radiotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/1754-9485.13874↗
  5. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1111/eci.14341↗
  6. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  7. The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer. Last author DOI 10.1007/s00432-023-05149-4↗
  8. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  9. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colo… Co-author DOI 10.1136/jitc-2022-006136↗
  10. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  11. The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as B… First author DOI 10.3390/jcm12051989↗
  12. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  13. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
  14. The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients' survival. Co-author DOI 10.1186/s12957-022-02803-y↗
  15. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Co-author DOI 10.3390/cancers14143528↗
  16. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resect… Co-author DOI 10.3390/cancers14153620↗
  17. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Co-author DOI 10.1016/j.ejso.2021.04.005↗
  18. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. Co-author DOI 10.1097/pas.0000000000001601↗
  19. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  20. Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. Last author DOI 10.3390/jcm10122700↗
  21. Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. Co-author DOI 10.1016/j.ejso.2020.02.001↗
  22. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001472↗
  23. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? Co-author DOI 10.3390/cancers12051341↗
  24. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. Co-author DOI 10.1016/j.ejso.2018.10.050↗
  25. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  26. Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data. Co-author DOI 10.1111/ans.13897↗
  27. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume r… Co-author DOI 10.1016/j.ejso.2017.06.012↗
  28. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.neo.2016.06.001↗
  29. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Co-author DOI 10.1158/1078-0432.ccr-15-0426↗
  30. Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. Last author DOI 10.3892/mco.2015.533↗
  31. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-13-3377↗
  32. Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-014-3554-4↗

Trials 1

  1. Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study Study chair NCT02358356↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 22 shared papers, 2014–2026 · strength 2.86
  2. Anubhav Mittal · 18 shared papers, 2017–2026 · strength 2.69
  3. Anthony James Gill · 18 shared papers, 2014–2026 · strength 2.17
  4. Stephen John Clarke · 15 shared papers, 2014–2026 · strength 2.04
  5. Sumit Sahni · 10 shared papers, 2020–2025 · strength 1.62
  6. Sarah Maloney · 5 shared papers, 2021–2025 · strength 0.82
  7. Angela S. Y. Chou · 5 shared papers, 2015–2026 · strength 0.79
  8. Josef Gillson · 4 shared papers, 2020–2025 · strength 0.78
  9. George Hruby · 6 shared papers, 2017–2025 · strength 0.74
  10. Malinda Itchins · 6 shared papers, 2017–2023 · strength 0.65
  11. Christopher Bahdah Nahm · 6 shared papers, 2017–2022 · strength 0.63
  12. Emily K. Colvin · 4 shared papers, 2019–2023 · strength 0.57
  13. David Lok Hang Chan · 4 shared papers, 2015–2025 · strength 0.55
  14. Terence C. Chua · 4 shared papers, 2017–2021 · strength 0.35
  15. Adnan M. Nagrial · 3 shared papers, 2015–2024 · strength 0.32
  16. Nigel Balfour Jamieson · 3 shared papers, 2019–2021 · strength 0.29
  17. Krishna Kotecha · 1 shared paper, 2026 · strength 0.28
  18. Simeng Li · 1 shared paper, 2026 · strength 0.28
  19. Hiro Masuda · 1 shared paper, 2026 · strength 0.28
  20. Taymin du Toit‐Thompson · 1 shared paper, 2025 · strength 0.27
  21. Sooin Byeon · 1 shared paper, 2025 · strength 0.23
  22. Joseph C. Y. Chan · 1 shared paper, 2025 · strength 0.22
  23. Jeremy Booth · 1 shared paper, 2025 · strength 0.22
  24. Lorraine A. Chantrill · 3 shared papers, 2015–2022 · strength 0.21
  25. Matthew H. Wong · 3 shared papers, 2014–2017 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.